<p>新泽西州沃伦，2026 年 2 月 27 日（全球新闻通讯社）——Tevogen（“Tevogen Bio Holdings Inc.” 或 “公司”）（纳斯达克：TVGN）今天宣布已签署一份非独占性、非约束性的意向书（“LoI”），以评估与一家知名全球合同研究组织（“CRO”）的潜在交易。如果交易达成，拟议的交易可能会扩展 Tevogen 的临床开发能力，并支持公司向一个产生收入的医疗企业的转型。</p>
<p>Tevogen 的创始人兼首席执行官 Ryan Saadi 博士表示：“收购 CRO 的潜在交易可能会引入产生收入的服务能力，同时允许我们优化内部试验执行。我们相信这种运营控制与服务收入的结合可能会增强盈利可见性，支持更具资本效率的增长模式，并提高患者的可负担性。”</p>
<p>拟议的交易仍需满足其他条件，包括尽职调查的完成、最终文件的谈判和签署、所需的批准以及满足惯例的成交条件。</p>
<p>Tevogen 还在积极考虑其他交易，重点关注生命科学相关业务；然而，无法保证任何此类交易会达成。</p>
<p><strong>关于 Tevogen</strong></p>
<p>Tevogen 是一家社会整合的医疗企业，建立在可负担性、效率和科学严谨的原则之上。该公司利用人工智能和精准 T 细胞治疗平台，以患者为中心和成本控制的运营模式，以及与全球技术领导者的合作，支持在多个治疗领域开发先进的、拯救生命的疗法和可扩展的解决方案，以改善更广泛的医疗系统。</p>
<p>Tevogen Bio 是公司的主要项目，已完成一项概念验证临床试验，证明其单 HLA 限制、基因未修饰的异体 T 细胞的潜力。Tevogen Bio 的产品线涵盖病毒学、肿瘤学和神经学，基于公司的专有 ExacTcell™平台构建。</p>
<p>Tevogen.AI 旨在通过加速目标检测、帮助降低失败率以及通过专有预测技术支持优化临床试验设计来转变药物开发。该平台利用来自领先技术提供商（包括微软和 Databricks）的云和数据服务，以推进其长期目标，即预测任何给定蛋白质-HLA 组合的蛋白质组，从而实现快速且成本高效的治疗发现。</p>
<p>Tevogen 正在探索未来的战略举措，可能包括国内仿制药、生物类似药、医疗设备和创新保险解决方案，以服务于医疗提供者。这些项目共同反映了 Tevogen 的使命，即通过更快、更高效和更公平的医疗模式推动可持续创新，扩大患者的可及性。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含某些前瞻性声明，包括但不限于与潜在交易及其潜在利益相关的声明；Tevogen 对其研究和制造能力的计划；对未来增长的预期；对医疗保健和生物制药行业的预期；以及 Tevogen 对其产品候选者的开发、潜在利益和患者获取的预期。前瞻性声明有时可以通过诸如 “可能”、“可以”、“将”、“期望”、“预期”、“可能”、“潜在”、“目标”、“机会”、“项目”、“相信”、“未来” 等词语及其反义词来识别。这些声明基于管理层截至本新闻稿日期的期望、假设、估计、预测和信念，并受到许多因素的影响，包括已知和未知的风险、延迟、不确定性以及其他不在公司控制范围内的因素，这些因素可能导致公司的实际结果、表现或成就与这些前瞻性声明所表达或暗示的结果、表现或其他期望存在重大差异。</p>
<p>可能导致实际结果、表现或成就与前瞻性声明中所表达或暗示的内容存在差异的因素包括但不限于：与拟议交易的尽职调查和谈判相关的固有风险；交易可能无法以有利条款完成或根本无法完成的风险；交易的预期收益可能无法及时实现或根本无法实现的风险；Tevogen 竞争市场的变化，包括其竞争格局、技术演变或监管变化；国内和全球经济状况的变化；Tevogen 可能无法执行其增长战略或在管理增长和扩展运营方面遇到困难的风险；Tevogen 可能无法开发和维持有效内部控制的风险；未能实现 Tevogen 的商业化和发展计划以及识别和实现额外机会的风险，这可能受到竞争、Tevogen 能否经济地增长和管理增长以及招聘和留住关键员工等因素的影响；Tevogen 可能未能跟上快速技术发展的步伐，以提供新颖和创新的产品和服务，或在不成功的新产品和服务上进行大量投资的风险；Tevogen 将需要筹集额外资金以充分实现其商业计划的风险；与开发、许可或收购新疗法相关的风险；与 Tevogen 业务相关的监管诉讼或程序的风险；在执行、成本和完成临床前研究和临床试验中固有的不确定性；与监管审查、批准和商业开发相关的风险；与知识产权保护相关的风险；Tevogen 的有限运营历史；以及在 Tevogen 最近的 10-K 表格年度报告和随后向 SEC 提交的文件中讨论或引用的因素。</p>
<p>您不应过度依赖前瞻性声明，因为这些声明仅在作出时有效。Tevogen 不承担更新任何前瞻性声明的义务，除非适用法律要求。</p>
<p><strong>联系方式</strong></p>
<p>Tevogen Bio 公共关系部</p>
<p>电话：1 877 TEVOGEN，分机 701</p>
<p>Communications@Tevogen.com</p>
<p>与此公告相关的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/aa22e271-a8d5-479c-b655-0c3be590c7b7 获取。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMk16QTJOeU0zTkRVNU56QTRJekl5T0RrNU1UYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMk16QTJOeU0zTkRVNU56QTRJekl5T0RrNU1UYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmQ1NDYyNTItZTY1Yi00ZjE4LTkxODktYmRhZDUxODViZDY1LTEzMDE0NjctMjAyNi0wMi0yNy1lbg==/tiny/Tevogen-Bio-Inc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmQ1NDYyNTItZTY1Yi00ZjE4LTkxODktYmRhZDUxODViZDY1LTEzMDE0NjctMjAyNi0wMi0yNy1lbg==/tiny/Tevogen-Bio-Inc.png"/></p>

标普生物技术 3 倍做空 - Direxion

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>Tevogen Bio Holdings Inc.（纳斯达克代码：TVGN）已签署一份非约束性意向书，以评估潜在收购一家全球合同研究组织（CRO）。此举旨在增强 Tevogen 的临床开发能力，并支持其转型为一个产生收入的医疗企业。首席执行官 Ryan Saadi 博士强调，此次收购可能改善运营控制和服务收入，最终增强盈利可见性。该交易需经过尽职调查和其他惯常条件的审查。Tevogen 还在探索其他与生命科学相关的交易，但无法保证这些交易的完成</p>

<p>WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterprise.</p>
<div class="lb-trans"><p>新泽西州沃伦，2026 年 2 月 27 日（全球新闻通讯社）——Tevogen（“Tevogen Bio Holdings Inc.” 或 “公司”）（纳斯达克：TVGN）今天宣布已签署一份非独占性、非约束性的意向书（“LoI”），以评估与一家知名全球合同研究组织（“CRO”）的潜在交易。如果交易达成，拟议的交易可能会扩展 Tevogen 的临床开发能力，并支持公司向一个产生收入的医疗企业的转型。</p>
</div><p>Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, “The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing us to optimize trial execution internally. We believe this combination of operational control and service revenue may strengthen earnings visibility, support a more capital-efficient growth model, and enhance patient affordability.”</p>
<div class="lb-trans"><p>Tevogen 的创始人兼首席执行官 Ryan Saadi 博士表示：“收购 CRO 的潜在交易可能会引入产生收入的服务能力，同时允许我们优化内部试验执行。我们相信这种运营控制与服务收入的结合可能会增强盈利可见性，支持更具资本效率的增长模式，并提高患者的可负担性。”</p>
</div><p>The proposed transaction remains subject to, among other things, completion of due diligence, negotiation and execution of definitive documentation, required approvals, and satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>拟议的交易仍需满足其他条件，包括尽职调查的完成、最终文件的谈判和签署、所需的批准以及满足惯例的成交条件。</p>
</div><p>Tevogen is also actively considering other transactions with a focus on life sciences-related businesses; however, there can be no assurance that any such transaction will be consummated.</p>
<div class="lb-trans"><p>Tevogen 还在积极考虑其他交易，重点关注生命科学相关业务；然而，无法保证任何此类交易会达成。</p>
</div><p><strong>About Tevogen</strong></p>
<div class="lb-trans"><p><strong>关于 Tevogen</strong></p>
</div><p>Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.</p>
<div class="lb-trans"><p>Tevogen 是一家社会整合的医疗企业，建立在可负担性、效率和科学严谨的原则之上。该公司利用人工智能和精准 T 细胞治疗平台，以患者为中心和成本控制的运营模式，以及与全球技术领导者的合作，支持在多个治疗领域开发先进的、拯救生命的疗法和可扩展的解决方案，以改善更广泛的医疗系统。</p>
</div><p>Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.</p>
<div class="lb-trans"><p>Tevogen Bio 是公司的主要项目，已完成一项概念验证临床试验，证明其单 HLA 限制、基因未修饰的异体 T 细胞的潜力。Tevogen Bio 的产品线涵盖病毒学、肿瘤学和神经学，基于公司的专有 ExacTcell™平台构建。</p>
</div><p>Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.</p>
<div class="lb-trans"><p>Tevogen.AI 旨在通过加速目标检测、帮助降低失败率以及通过专有预测技术支持优化临床试验设计来转变药物开发。该平台利用来自领先技术提供商（包括微软和 Databricks）的云和数据服务，以推进其长期目标，即预测任何给定蛋白质-HLA 组合的蛋白质组，从而实现快速且成本高效的治疗发现。</p>
</div><p>Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.</p>
<div class="lb-trans"><p>Tevogen 正在探索未来的战略举措，可能包括国内仿制药、生物类似药、医疗设备和创新保险解决方案，以服务于医疗提供者。这些项目共同反映了 Tevogen 的使命，即通过更快、更高效和更公平的医疗模式推动可持续创新，扩大患者的可及性。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains certain forward-looking statements, including without limitation statements relating to: the potential transaction and the potential benefits of the transaction; Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.</p>
<div class="lb-trans"><p>本新闻稿包含某些前瞻性声明，包括但不限于与潜在交易及其潜在利益相关的声明；Tevogen 对其研究和制造能力的计划；对未来增长的预期；对医疗保健和生物制药行业的预期；以及 Tevogen 对其产品候选者的开发、潜在利益和患者获取的预期。前瞻性声明有时可以通过诸如 “可能”、“可以”、“将”、“期望”、“预期”、“可能”、“潜在”、“目标”、“机会”、“项目”、“相信”、“未来” 等词语及其反义词来识别。这些声明基于管理层截至本新闻稿日期的期望、假设、估计、预测和信念，并受到许多因素的影响，包括已知和未知的风险、延迟、不确定性以及其他不在公司控制范围内的因素，这些因素可能导致公司的实际结果、表现或成就与这些前瞻性声明所表达或暗示的结果、表现或其他期望存在重大差异。</p>
</div><p>Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: risks inherent in diligence and negotiation of the proposed transaction; the risk that the transaction may not be consummated on favorable terms or at all; the risk that the expected benefits of the transaction may not be realized on a timely basis or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s most recent Annual Report on Form 10-K and subsequent filings with the SEC.</p>
<div class="lb-trans"><p>可能导致实际结果、表现或成就与前瞻性声明中所表达或暗示的内容存在差异的因素包括但不限于：与拟议交易的尽职调查和谈判相关的固有风险；交易可能无法以有利条款完成或根本无法完成的风险；交易的预期收益可能无法及时实现或根本无法实现的风险；Tevogen 竞争市场的变化，包括其竞争格局、技术演变或监管变化；国内和全球经济状况的变化；Tevogen 可能无法执行其增长战略或在管理增长和扩展运营方面遇到困难的风险；Tevogen 可能无法开发和维持有效内部控制的风险；未能实现 Tevogen 的商业化和发展计划以及识别和实现额外机会的风险，这可能受到竞争、Tevogen 能否经济地增长和管理增长以及招聘和留住关键员工等因素的影响；Tevogen 可能未能跟上快速技术发展的步伐，以提供新颖和创新的产品和服务，或在不成功的新产品和服务上进行大量投资的风险；Tevogen 将需要筹集额外资金以充分实现其商业计划的风险；与开发、许可或收购新疗法相关的风险；与 Tevogen 业务相关的监管诉讼或程序的风险；在执行、成本和完成临床前研究和临床试验中固有的不确定性；与监管审查、批准和商业开发相关的风险；与知识产权保护相关的风险；Tevogen 的有限运营历史；以及在 Tevogen 最近的 10-K 表格年度报告和随后向 SEC 提交的文件中讨论或引用的因素。</p>
</div><p>You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.</p>
<div class="lb-trans"><p>您不应过度依赖前瞻性声明，因为这些声明仅在作出时有效。Tevogen 不承担更新任何前瞻性声明的义务，除非适用法律要求。</p>
</div><p><strong>Contacts</strong></p>
<div class="lb-trans"><p><strong>联系方式</strong></p>
</div><p>Tevogen Bio Communications</p>
<div class="lb-trans"><p>Tevogen Bio 公共关系部</p>
</div><p>T: 1 877 TEVOGEN, Ext 701</p>
<div class="lb-trans"><p>电话：1 877 TEVOGEN，分机 701</p>
</div><p>Communications@Tevogen.com</p>
<div class="lb-trans"><p>Communications@Tevogen.com</p>
</div><p>A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/aa22e271-a8d5-479c-b655-0c3be590c7b7</p>
<div class="lb-trans"><p>与此公告相关的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/aa22e271-a8d5-479c-b655-0c3be590c7b7 获取。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMk16QTJOeU0zTkRVNU56QTRJekl5T0RrNU1UYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY2MzA2NyM3NDU5NzA4IzIyODk5MTc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmQ1NDYyNTItZTY1Yi00ZjE4LTkxODktYmRhZDUxODViZDY1LTEzMDE0NjctMjAyNi0wMi0yNy1lbg==/tiny/Tevogen-Bio-Inc.png" alt="" original-src="https://ml.globenewswire.com/media/ZmQ1NDYyNTItZTY1Yi00ZjE4LTkxODktYmRhZDUxODViZDY1LTEzMDE0NjctMjAyNi0wMi0yNy1lbg==/tiny/Tevogen-Bio-Inc.png"/></p>

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization  | TVGN Stock News

StockTitan

纽交所高增长板生物技术指数 ETF - First Trust

TEVOGEN BIO HOLDINGS INC C/WTS 14/02/2029 (TO PUR COM)

纳斯达克生物科技指数 ETF - iShares Nasdaq

Invesco Nasdaq Biotechnology ETF

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

Tevogen Bio

Tevogen 签署意向书以评估收购一家合同研究组织的潜力 | TVGN 股票新闻